Skip to content

Frontlight ResearchEarly access

Trial site

Northwest Medical Specialties

Tacoma, Washington 98405, United StatesNot linked to an institution yet

27running trials
6closed trials

The trials here

What the 33 trials at this site are about, from their registry records.

Conditions: Lung cancer12 trials
Metastatic breast cancer7 trials
Gastric and oesophageal cancer6 trials
Childhood cancers4 trials
Prostate cancer4 trials
Colorectal cancer3 trials
Head and neck cancer3 trials
Kidney cancer3 trials
Melanoma3 trials
Bladder cancer2 trials
Cervical cancer2 trials
Chronic myeloid leukaemia2 trials
and 12 more
Phase: Phase 313 trials
Phase 29 trials
Phase 16 trials
Phase 1/23 trials
Phase 2/31 trial
Status: Active, not recruiting14 trials
Recruiting13 trials
Completed4 trials
Terminated2 trials
Lead sponsor: Hoffmann-La Roche6 trials
Novartis Pharmaceuticals5 trials
BeOne Medicines3 trials
American Society of Clinical Oncology2 trials
Daiichi Sankyo2 trials
and 13 more

Running trials

Recruiting
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
NCT07091019· Novartis Pharmaceuticals· Source
Contact: Ali Dadla (principal investigator)
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400· Phase 3· BeOne Medicines· Source
Contact: BeOne Medicines
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277· Phase 3· Novartis Pharmaceuticals· Source
Contact: Patricia Walsh
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752· Phase 3· Novartis Pharmaceuticals· Source
Contact: Patricia Walsh
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Contact: Ying Li
Recruiting
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852· Phase 3· American Society of Clinical Oncology· Source
Contact: Jodi Thiel
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402· Phase 1· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Source
Contact: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· Phase 3· Hoffmann-La Roche· Source
Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379· Phase 1/2· Neonc Technologies, Inc.· Source
Contact: Sheila Marsh
Active, not recruiting
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906· Phase 1· Olema Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132· Phase 1/2· Synthekine· Source
Active, not recruiting
A Study of NDI 1150-101 in Patients With Solid Tumors
NCT05128487· Phase 1/2· Nimbus Saturn, Inc.· Source
Recruiting
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114· Phase 1· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Active, not recruiting
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT04485013· Phase 1· Tizona Therapeutics, Inc· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499· Phase 2/3· Hoffmann-La Roche· Source
Active, not recruiting
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
NCT03260491· Phase 1· Daiichi Sankyo· Source
Active, not recruiting
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418· Phase 3· Hoffmann-La Roche· Source
Recruiting
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535· Phase 2· American Society of Clinical Oncology· Source
Contact: Jennifer Spokely
Active, not recruiting
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949· Phase 2· Partner Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Terminated
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
NCT05588609· Phase 2· Partner Therapeutics, Inc.· Source
Terminated
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT05169437· Phase 2· Tempus AI· Source
Completed
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source
Completed
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Completed
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
NCT03822468· Phase 2· Novartis Pharmaceuticals· Source
Completed
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
NCT02892123· Phase 1· Jazz Pharmaceuticals· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error

Northwest Medical Specialties: trial site – Frontlight Research